Regulatory issues

Field trials in USA in 2014, 2015.

Food Addit­ives:
GRAS status for our first colicin products in 2015 (GRN593), 2017 (GRN676) and 2018 (GRN775), GRAS status for our thau­matin sweetener in 2018 (GRN738) and 2020 (GRN910 and GRN920).
GRAS status for Clostridium bacterio­phage endolysins (GRN802) and bacteri­ocin prepar­a­tions specific to Salmon­ella (GRN824) in 2019.

GMP certi­fic­a­tion of the facility in Halle, Germany (divested with ICON); successful Phase I trials in USA with NHL cancer vaccine; Phase I-II with ZMapp anti-Ebola therapy (based on our tech­no­logy).

Clear regu­latory path for products based on our propri­etory manu­fac­turing process.